Advertisement

Myelodysplastic Syndromes

Diagnosis - Prognosis - Therapy

  • Uwe Platzbecker
  • Pierre Fenaux

Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Table of contents

  1. Front Matter
    Pages i-v
  2. Diagnostics and Prognosis

    1. Front Matter
      Pages 1-1
    2. Katja Sockel, Frank Kroschinsky, Uta Oelschlaegel, Arjan A. van de Loosdrecht
      Pages 3-13
    3. Austin G. Kulasekararaj, Olivier Kosmider, Ghulam J. Mufti
      Pages 15-37
    4. Stefan Dirnhofer
      Pages 39-41
    5. Detlef Haase, Charikleia Kelaidi
      Pages 43-64
    6. Matthieu Duchmann, Nolwenn Lucas, Raphael Itzykson, Eric Solary
      Pages 65-79
  3. Therapy

    1. Front Matter
      Pages 81-81
    2. S. Park, K. Götze
      Pages 83-95
    3. Anna Mies, Amit Verma, Uwe Platzbecker
      Pages 97-104
    4. Norbert Gattermann, Christian Rose
      Pages 105-118
    5. Aristoteles Giagounidis, Lionel Adès
      Pages 119-129
    6. Ulrich Germing, Pierre Fenaux
      Pages 131-139
    7. Bart L. Scott, M. Robin
      Pages 141-157

About this book

Introduction

This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation.

Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.

Keywords

Myelodysplastic Syndromes Anemia Erythropoietic Stimulating Agents Hypomethylating Agents Iron Chelation Therapy

Editors and affiliations

  • Uwe Platzbecker
    • 1
  • Pierre Fenaux
    • 2
  1. 1.Medizinische Klinik und Poliklinik 1Universitätsklinikum Dresden Medizinische Klinik und Poliklinik 1DresdenGermany
  2. 2.Department of HematologyHospital Saint LouisParisFrance

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-76879-3
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-76878-6
  • Online ISBN 978-3-319-76879-3
  • Series Print ISSN 2197-9766
  • Series Online ISSN 2197-9774
  • Buy this book on publisher's site
Industry Sectors
Pharma
Biotechnology